Recent Advances in Patient Treatment and Care (Track)
Podocyturia in Patients Treated with Vegf Blocking Therapy for Cancer
Vesna D. Garovic Mayo Clinic, Rochester, MN, USA
Abstract:
Anti-VEGF therapy has been associated previously with renal side effects, including proteinuria. We aimed to study whether podocyturia, i.e., urinary excretion of viable podocytes, is present in patients who, while undergoing anti-VEGF therapy, develop proteinuria. In addition, we compared urinary podocyte excretion among patients on anti-VEGF therapy with proteinuria ranging from 101 to 9720 mg/24 hour urine. Freshly voided urine was collected and used for podocyte cell culture.
Our results show a higher degree of podocyturia in patients undergoing anti-VEGF therapy with proteinuria in excess of 2 gr/24 hour urine compared to those treated with the same agents and proteinuria <0.5 gr/24 hour urine.
Type of Ca
Age /Sex
Anti-VEGF
GFR
Proteinuria
Cells /HPF
Cholangio Ca
68/F
B
66
420 mg/d
0
Renal Cell Ca
60/M
S/nib
39
101 mg/d
1
Colorectal Ca
55/F
B
137
1+ dipstick
1
Colon Ca
66/F
B + S/nib
77
330 mg/d
0
GBM
59/F
B + S/nib
78
152 mg/d
1
Renal Cell Ca
73/M
B
63
2144 mg/d
>3
Renal Cell Ca
67/F
Sunitib
43
2112 mg/d
>3
SBC
68/M
B
59
6361 mg/d
>3
GBM
70/M
S/nib
70
9720 mg/d
>9
Ca: cancer; GBM: glioblastoma multiforme; SBC: small bowel carcinoid; B: bevacizumab; S/nib: sorafenib; HPF: high power field.
